A Charlotte company with ties to UNC-Charlotte is advertising a brand new scientific check designed to support monitor girls for breast melanoma. WFAE's Mark Rumsey reports.
Mark Rumsey reports on a brand new breast cancer screening method being marketed by a Charlotte company.
Researchers at UNC-Charlotte agree with they've developed a method to detect breast cancer it really is more advantageous than mammograms. it's a blood screening that in all probability most exceptionally detects melanoma in ladies who've dense breast tissue. average mammograms regularly leave out those tumors.
the new check become developed via OncoTAb, an organization spun off from the biotech software at UNC-Charlotte. OncoTAb co-founder, Pinku Mukherjee says the blood examine uses an antibody biomarker to establish a protein that's found in more than 90% of breast cancers. "it be a protein this is released from the cancer tissue into the bloodstream, so this protein is then picked up by our examine," says Mukherjee.
UNC-Charlotte owns the patent to OncoTAb's screening know-how, and Mukherjee chairs the institution's biological Sciences branch.
The company is rarely suggesting that girls cease getting mammograms, and Mukherjee says women should not count on a single system to ensure that breast cancer is caught as early as possible. "there's no certain-shot, one-bullet check at the moment," says Mukherjee. "We feel that our verify may well be an adjunct to different imaging, but there's no one test."
OncoTAb says women who wish to use the enterprise's blood screening know-how to video display for breast melanoma will want a physician's prescription, beneath FDA laws. A spokeswoman for the FDA says the agency can not comment on OncoTAb's screening technology. The FDA has allowed some labs to present such checks without federal approval.
results are posted to a patient portal inside seven company days. to date, coverage doesn't cover the $199 charge of each blood test.
0 komentar:
Posting Komentar